0.5993
price down icon15.76%   -0.1121
after-market Handel nachbörslich: .62 0.0207 +3.45%
loading
Schlusskurs vom Vortag:
$0.7114
Offen:
$0.6942
24-Stunden-Volumen:
4.88M
Relative Volume:
9.45
Marktkapitalisierung:
$77.63M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.47M
KGV:
-1.0514
EPS:
-0.57
Netto-Cashflow:
$-124.27M
1W Leistung:
-34.14%
1M Leistung:
-41.82%
6M Leistung:
-64.64%
1J Leistung:
-58.38%
1-Tages-Spanne:
Value
$0.55
$0.70
1-Wochen-Bereich:
Value
$0.55
$1.00
52-Wochen-Spanne:
Value
$0.55
$4.44

Prokidney Corp Stock (PROK) Company Profile

Name
Firmenname
Prokidney Corp
Name
Telefon
336-999-7028
Name
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Name
Mitarbeiter
204
Name
Twitter
Name
Nächster Verdiensttermin
2024-12-09
Name
Neueste SEC-Einreichungen
Name
PROK's Discussions on Twitter

Vergleichen Sie PROK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
PROK
Prokidney Corp
0.5993 77.63M 0 -35.47M -124.27M -0.57
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Prokidney Corp Stock (PROK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-09-30 Eingeleitet JP Morgan Neutral
2024-09-10 Eingeleitet Guggenheim Buy
2024-03-07 Fortgesetzt Morgan Stanley Equal-Weight
2024-01-02 Herabstufung BofA Securities Buy → Neutral
2023-07-25 Eingeleitet BTIG Research Buy
2022-12-21 Eingeleitet Jefferies Buy
2022-11-10 Eingeleitet Morgan Stanley Equal-Weight
2022-10-18 Eingeleitet UBS Buy
2022-10-14 Eingeleitet Citigroup Buy
2022-09-23 Eingeleitet BofA Securities Buy
2022-09-02 Eingeleitet Evercore ISI Outperform
Alle ansehen

Prokidney Corp Aktie (PROK) Neueste Nachrichten

pulisher
Mar 29, 2025

Bank of New York Mellon Corp Has $388,000 Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World

Mar 29, 2025
pulisher
Mar 27, 2025

Here's Why We're Watching ProKidney's (NASDAQ:PROK) Cash Burn Situation - Yahoo Finance

Mar 27, 2025
pulisher
Mar 21, 2025

Down -38% in 4 Weeks, Here's Why You Should You Buy the Dip in PROKIDNEY CP (PROK) - Yahoo Finance

Mar 21, 2025
pulisher
Mar 20, 2025

PROK stock touches 52-week low at $0.94 amid market challenges - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

ProKidney Corp reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 20, 2025
pulisher
Mar 18, 2025

ProKidney Hold Rating: Balancing Developmental Progress and Financial Stability Amid Uncertainty - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

ProKidney Corp (PROK) Reports $163.3 Million Net Loss for 2024, - GuruFocus.com

Mar 18, 2025
pulisher
Mar 18, 2025

ProKidney reports larger loss in 2024 as production resumes - Winston-Salem Journal

Mar 18, 2025
pulisher
Mar 17, 2025

PROKIDNEY CORP. SEC 10-K Report - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

ProKidney CEO cites 'significant progress' after regenerative medicine company loses $163M in 2024 - The Business Journals

Mar 17, 2025
pulisher
Mar 17, 2025

ProKidney reports FY24 EPS (62c), consensus (59c) - TipRanks

Mar 17, 2025
pulisher
Mar 17, 2025

ProKidney Corp. Reports 2024 Financial Results and Milestones in Rilparencel Development for Chronic Kidney Disease - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

ProKidney Reports Full Year 2024 Financial Results and Business Highlights - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

FDA Fast-Tracks ProKidney's CKD Treatment: $358M War Chest Fuels Breakthrough Development - StockTitan

Mar 17, 2025
pulisher
Mar 13, 2025

Top 3 Health Care Stocks You'll Regret Missing This Quarter - Benzinga

Mar 13, 2025
pulisher
Mar 13, 2025

ProKidney (PROK) Expected to Announce Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Feb 28, 2025

ProKidney (NASDAQ:PROK) Stock Price Down 2.7%Here's What Happened - MarketBeat

Feb 28, 2025
pulisher
Feb 27, 2025

ProKidney stock hits 52-week low at $1.34 amid market challenges - Investing.com Australia

Feb 27, 2025
pulisher
Feb 26, 2025

ProKidney stock hits 52-week low at $1.34 amid market challenges By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 26, 2025

Head to Head Review: ProKidney (NASDAQ:PROK) and Adaptimmune Therapeutics (NASDAQ:ADAP) - Defense World

Feb 26, 2025
pulisher
Feb 25, 2025

Owning 32% shares,institutional owners seem interested in ProKidney Corp. (NASDAQ:PROK), - Yahoo

Feb 25, 2025
pulisher
Feb 13, 2025

ProKidney Corp (NASDAQ: PROK) Has Great Upside Potential - Stocks Register

Feb 13, 2025
pulisher
Feb 06, 2025

ProKidney Corp [PROK] Chief Regulatory Officer makes an insider sale of 16,412 shares worth 41,030. - Knox Daily

Feb 06, 2025
pulisher
Feb 03, 2025

JPMorgan Chase & Co. Purchases 18,472 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World

Feb 03, 2025
pulisher
Feb 01, 2025

Kuehn Law Encourages Investors of ProKidney Corp. to Contact Law Firm - The Malaysian Reserve

Feb 01, 2025
pulisher
Jan 31, 2025

2025 Will Be A Major Year For ProKidney’s Rilparencel In CKD Treatment (NASDAQ:PROK) - Seeking Alpha

Jan 31, 2025
pulisher
Jan 27, 2025

US Penny Stocks: 3 Picks With Market Caps Under $300M - Simply Wall St

Jan 27, 2025
pulisher
Jan 23, 2025

ProKidney secures out-of-market buyer, $20.5 million price tag for Greensboro site - The Business Journals

Jan 23, 2025
pulisher
Jan 23, 2025

ProKidney's high-profile Greensboro plant initiative ends with planned $20 million sale of property - Winston-Salem Journal

Jan 23, 2025
pulisher
Jan 22, 2025

ProKidney (NASDAQ:PROK) Trading 8.7% HigherStill a Buy? - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Insiders In ProKidney Still Down 26% On US$54.7m Investment - Simply Wall St

Jan 22, 2025
pulisher
Jan 21, 2025

Barclays PLC Has $281,000 Position in ProKidney Corp. (NASDAQ:PROK) - Defense World

Jan 21, 2025
pulisher
Jan 20, 2025

568,647 Shares in ProKidney Corp. (NASDAQ:PROK) Purchased by Hennion & Walsh Asset Management Inc. - MarketBeat

Jan 20, 2025
pulisher
Jan 16, 2025

Jane Street Group LLC Has $78,000 Stock Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World

Jan 16, 2025
pulisher
Jan 09, 2025

ProKidney Corp (PROK) Analyst Thoughts: How High Can It Go? - Stocks Register

Jan 09, 2025
pulisher
Jan 07, 2025

ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 07, 2025
pulisher
Jan 07, 2025

ProKidney to Present at J.P. Morgan Healthcare Conference, Spotlight on CKD Cell Therapy - StockTitan

Jan 07, 2025
pulisher
Jan 06, 2025

Geode Capital Management LLC Grows Stock Position in ProKidney Corp. (NASDAQ:PROK) - Defense World

Jan 06, 2025
pulisher
Jan 06, 2025

Geode Capital Management LLC Raises Stake in ProKidney Corp. (NASDAQ:PROK) - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

Barclays PLC Purchases 124,667 Shares of ProKidney Corp. (NASDAQ:PROK) - Defense World

Jan 06, 2025
pulisher
Jan 05, 2025

One ProKidney Insider Raised Their Stake In The Previous Year - Yahoo Finance

Jan 05, 2025
pulisher
Jan 02, 2025

Stories to Watch in 2025: Will ProKidney change its Winston-Salem plans after abandoning $458M Greensboro facility? - The Business Journals

Jan 02, 2025
pulisher
Jan 02, 2025

Cortexyme (NASDAQ:CRTX) vs. ProKidney (NASDAQ:PROK) Head to Head Comparison - Defense World

Jan 02, 2025
pulisher
Jan 01, 2025

State Street Corp Has $2.74 Million Holdings in ProKidney Corp. (NASDAQ:PROK) - Defense World

Jan 01, 2025
pulisher
Dec 31, 2024

ProKidney (NASDAQ:PROK) Shares Gap UpStill a Buy? - MarketBeat

Dec 31, 2024
pulisher
Dec 30, 2024

TBJ's Top 24 of '24: ProKidney backs out of Guilford deal, invests in W-S facilities (No. 4) - Triad Business Journal

Dec 30, 2024

Finanzdaten der Prokidney Corp-Aktie (PROK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):